THTakaaki Hasegawa

Takaaki Hasegawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takaaki Hasegawa has a total of 213 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations

    by Yoshinobu Matsuda, Jun Kako, Takaaki Hasegawa, Saho Wada, Hitoshi Tanimukai, Shinichiro Inoue, Kaori Shinsato, Yusuke Kanno, Tetsuro Ishida, Yuichi Kitaura, et al.

    Background: The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations. Methods: These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated. Results: Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients. Conclusions: These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.

  • Open Access

    Nonpharmacological interventions for preventing delirium in adult patients with cancer: a systematic review and meta-analysis

    by Yusuke Kanno, Kaoru Shinsato, Jun Kako, Yoshinobu Matsuda, Shinichiro Inoue, Hitoshi Tanimukai, Saho Wada, Takaaki Hasegawa

    Purpose: To determine whether nonpharmacological interventions reduce delirium incidence in adult patients with cancer and to identify effective intervention strategies. Method: We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, CENTRAL, CINAHL, and Ichushi-Web were searched through September 30, 2024, for randomized controlled trials (RCTs). Two authors independently extracted data, assessed the risk of bias using the Cochrane Risk of Bias 2 tool, and evaluated the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. The primary outcome was delirium incidence. A random-effects model was used for the meta-analysis. The study protocol was registered with UMIN-CTR (No. UMIN000051804; registered August 2, 2023). Results: Overall, 12 RCTs involving 2,747 patients were included. Interventions were categorized into multicomponent interventions, bright light therapy, rehabilitation, and anesthesia or oxygen management. The meta-analysis of five trials showed that multicomponent interventions significantly reduced delirium incidence (risk ratio [RR], 0.43; 95% confidence interval [CI], 0.31–0.60; moderate-certainty evidence), with benefit predominantly observed in postoperative settings. The evidence for bright light therapy was inconclusive (RR, 0.31; 95%CI, 0.07–1.31; very low-certainty evidence). Most of the included studies had concerns regarding the risk of bias, mainly due to a lack of blinding. Conclusion: Multicomponent nonpharmacological interventions may reduce delirium incidence in adult patients with cancer, particularly in postoperative or perioperative settings. However, the certainty of evidence is moderate, and the included studies vary in patient populations, intervention components, and healthcare settings. Evidence for standalone interventions and prevention strategies in palliative or end-of-life care remains limited and inconclusive.


  • Open Access

    Implementation of artificial intelligence in palliative and supportive care for people with cancer: A scoping review

    by Shino Kikuchi, Masatsugu Sakata, Takaaki Hasegawa, Sakiko Wada, Satoshi Funada, Mari Makishi, Tatsuo Akechi

    Background: Cancer remains a leading global health burden. Artificial intelligence offers new opportunities to address complex physical and psychological symptoms in palliative and supportive cancer care. Despite rapid advances, including large language models, these technologies have not been consistently reviewed in this context, highlighting a gap in the synthesised literature. Aim: To map current evidence on how artificial intelligence is implemented in palliative and supportive care for people with cancer and their caregivers, and to identify associated challenges and future directions. Design: Scoping review guided by the Joanna Briggs Institute (JBI) framework. Data sources: We searched PubMed, CENTRAL, PsycINFO, and CINAHL databases, along with grey literature, up to 17 September 2024, and manually screened reference lists. Results: Of 2618 records screened, 199 studies were included. Most applications supported healthcare professionals, mainly for predictive purposes such as prognosis, symptom monitoring, and treatment-related adverse events. Machine learning was the predominant approach, reflecting reliance on structured clinical data. Publications increased markedly after 2020, with a sharp rise from 2022 onwards. Only 26 studies involved direct use by people with cancer or their caregivers, and large language model–based applications remained rare, indicating limited patient-facing use. Conclusions: Artificial intelligence is increasingly being applied in palliative and supportive care, yet applications designed for direct patient or caregiver use remain scarce. Further efforts should prioritise the development and validation of ethically sound, clinically integrated artificial intelligence tools to support person-centred palliative and supportive care.


  • Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer

    by Yosuke Sugiyama, Yoshihiko Tasaki, Yoshihisa Mimura, Taku Naiki, Kunihiro Odagiri, Tomoya Kataoka, Toshiki Etani, Moeko Iida, Takaaki Hasegawa, Yosuke Furukawa, et al.

    Background: While opioid analgesics are widely used to manage moderate-to-severe cancer-related pain, dosing is mostly based on subjective pain reports rather than objective physiological indicators, potentially contributing to inconsistent dosing and suboptimal pain control. This study investigated whether model-predicted oxycodone serum concentrations could guide opioid dosing and whether wearable-derived heart rate and step count, combined with these predictions, could complement conventional numerical rating scale (NRS) pain assessments. Methods: Sixteen patients with advanced genitourinary cancer receiving oxycodone were prospectively monitored. Clinically collected serum concentrations were used to simulate individual pharmacokinetic profiles. Pain intensity was assessed using the NRS, and physiological parameters were recorded using wearable devices. Linear mixed-effects models were constructed to evaluate the associations between simulated serum oxycodone concentrations, NRS, and physiological variables. Results: In the linear mixed-effects model, simulated serum oxycodone concentrations were significantly associated with lower NRS scores (β = −0.26, P = .0177). Although neither heart rate nor step count independently predicted NRS, incorporating heart rate into the model improved the overall fit. Thus, heart rate may capture pain-related physiological responses not fully explained by oxycodone concentration alone, thereby enhancing the explanatory power of the model. Conclusions: Model-based simulated serum oxycodone concentrations may serve as an objective reference for individualized pain assessment and opioid titration. Combining wearable-derived physiological signals, particularly heart rate, with model-predicted oxycodone concentrations may further improve the precision and adaptability of pain management in palliative care.


  • Orexin receptor antagonists for delirium prevention: systematic review in cancer

    by Shuntaro Yasuda, Saki Harashima, Yoshinobu Matsuda, Shinichiro Inoue, Hitoshi Tanimukai, Saho Wada, Jun Kako, Takaaki Hasegawa

    Orexin receptor antagonists promote sleep by blocking receptors for orexin, a neurotransmitter that maintains wakefulness. Pharmacological interventions for modifying sleep-wake cycle disturbances have recently garnered increased attention for the prevention of delirium, and previous studies have demonstrated the efficacy of melatonin receptor agonists in the prevention of delirium. Orexin receptor antagonists are also a promising intervention to prevent delirium by modifying the sleep-wake cycle, and several studies have examined the efficacy of orexin receptor antagonists, either alone or in combination with ramelteon, in preventing delirium, particularly in acutely ill patients.

  • Quality Indicators in Psychological Care for Patients With Serious Illness: A Systematic Review

    by Takaaki Hasegawa, Toru Okuyama, Ryoichi Sadahiro, Yu Uneno, Yoshiaki Okamoto, Yusuke Kanno, Saho Wada, Shuji Inada, Yuri Igarashi, Hitoshi Tanimukai, et al.


  • Longitudinal changes in delirium motor subtypes among patients with advanced cancer in inpatient hospice and palliative care units: A secondary analysis of a multicenter cohort study

    by Takaaki Hasegawa, Masanori Mori, Takashi Yamaguchi, Kengo Imai, Yoshinobu Matsuda, Isseki Maeda, Yutaka Hatano, Hiroto Ishiki, Hiroyuki Otani

    The stability of delirium motor subtypes in palliative care is unknown. We examined the longitudinal changes in delirium motor subtypes during palliative care unit stay. We performed a secondary analysis of a multicenter observational study involving patients with advanced cancer. We assessed delirium, its motor subtypes, and symptoms including agitation (Memorial Delirium Assessment Scale [MDAS] item 9) and communication capacity (Communication Capacity Scale [CCS] item 4) at admission (T0), on the day of Palliative Performance Scale decline to 20 (T1, immediately before death), and daily until death. We obtained 9,251 delirium assessments from 1,633 patients: 31% experienced hypoactive delirium without hyperactive delirium and 35% experienced hyperactive or mixed delirium during their stay. As for stability, 57% of patients with hypoactive delirium and 57% of those with hyperactive or mixed delirium at T0 remained in the same subtype until death. Further, 17% of patients with hypoactive delirium at T0 developed hyperactive or mixed delirium during their stay. Moreover, 47% of patients assessed at both T0 and T1 had a CCS item 4 < 3 (maintained communication capacity) and MDAS item 9 < 2 (no moderate-to-severe agitation) at T1. Patients with delirium (hyperactive, mixed, or hypoactive) at T0 were less likely to maintain communication capacity without moderate-to-severe agitation at T1 than patients without delirium at T0, after adjusting for covariates. Considering the stability of delirium motor subtypes and the difficulty in balancing comfort with communication in palliative care, individualized delirium management goals should be discussed with caregivers.

  • Opioid switching to improve delirium symptoms in patients with cancer: a systematic review

    by Kousuke Yamanaka, Takaaki Hasegawa, Yoshinobu Matsuda, Shinichiro Inoue, Hitoshi Tanimukai, Saho Wada, Jun Kako, the Japan Psycho-Oncology Society/the Japanese Association of Supportive Care in Cancer’s Clinical Practice Guidelines for Delirium in Cancer Patients Group, Tetsuro Ishida, Tetsuya Ito, et al.

    Delirium is a common and distressing symptom in patients with cancer, while opioids-which are essential in managing cancer pain-can cause delirium. Opioid switching is a widely used strategy for the management of opioid-induced delirium; however, its efficacy is yet to be verified. This systematic review aimed to determine opioid switching's efficacy and safety for managing opioid-induced delirium in patients with cancer. This systematic review was conducted in accordance with the PRISMA guidelines. We searched four databases (PubMed, Cochrane Controlled Register of Trials, Cochrane Library, and Ichishi-Web) on September 6, 2023, with an updated PubMed search on October 20, 2024. Our review included studies on opioid switching for managing delirium in patients with cancer. If there were less than two randomized controlled trials (RCTs), we included observational studies. Data extraction and evaluation were independently conducted by two reviewers using the GRADE evaluation. The study protocol was registered (UMIN000051787). The literature search identified seven observational studies without a control group; however, no RCTs were found. Four observational studies reported improvements in the severity of delirium symptoms. No study reported worsening pain or dyspnea after opioid switching. According to the GRADE framework, all outcomes were graded very low on certainty. Although observational studies imply opioid switching's effectiveness for managing opioid-induced delirium in patients with cancer, there is a lack of RCTs and the level of evidence is very low. Thus, RCTs are warranted to confirm opioid switching's efficacy.


  • Open Access

    Efficacy and safety of combining low-dose methadone with ongoing opioid treatment for uncontrolled cancer pain: an open-label single-arm study

    by Takaaki Hasegawa, Toru Okuyama, Nana Suzuki, Yosuke Furukawa, Yoshihiko Tasaki, Moeko Iida, Asako Ito, Megumi Uchida, Yosuke Kubota, Shino Kikuchi, et al.

    Background: Pharmacological options for refractory cancer pain are limited. This study aimed to investigate the efficacy and safety of the combined use of low-dose methadone and ongoing opioid treatment for uncontrolled cancer pain. Methods: This was a prospective, open-label study. Participants were patients with uncontrolled cancer pain despite dose titration of opioids. Patients received low-dose methadone (starting dose of 5 or 10 mg/day) combined with another ongoing opioid therapy. The primary outcome was the proportion of responders (defined as ≥33% reduction in average pain intensity on the numerical rating scale [NRS]) on day 15. Pain intensity and adverse events according to the Patient-Reported Outcome Common Terminology Criteria for Adverse Events were evaluated at baseline, on days 8 and 15. Results: Nineteen patients participated in this study, 11 (57.9%) of whom had neuropathic pain. The mean daily oral morphine equivalent dose before combination was 112.6 mg. The primary outcome occurred in 13 (68.4%) of patients (95% CI, 43.4 to 87.4). The mean average NRS was 5.9 at baseline, which decreased significantly to 4.2 and 3.3 on days 8 and 15 (P < .001), respectively. The worst pain intensity on NRS decreased significantly over time. Adverse effects, including nausea, vomiting, constipation, and somnolence, which were new or had worsened from baseline, were reported in 26.3%, 26.3%, 5.3%, and 26.3%, respectively. Delirium was observed in one patient. Conclusion: Low-dose methadone with ongoing opioid treatment shows potential efficacy in the management of uncontrolled pain with acceptable adverse events. ClinicalTrials.gov identifier: UMIN000038924


  • Open Access

    Pharmacological Strategies for Pain Relief in Patients with Terminal Delirium: A Secondary Data Analysis

    by Takaaki Hasegawa, Masanori Mori, Takashi Yamaguchi, Kengo Imai, Yoshinobu Matsuda, Isseki Maeda, Yutaka Hatano, Hiroto Ishiki, Hiroyuki Otani

    Background: Terminally ill cancer patients often experience pain and delirium. However, opioids administered for pain management may exacerbate patients’ delirium. Objectives: To explore the real-world symptom trajectory associated with pharmacological interventions, including opioids and antipsychotics, in patients with cancer pain and terminal delirium. Design: A secondary analysis of a multicenter prospective observational study. Setting/Subjects: Adult patients admitted to inpatient hospice or palliative care units in Japan. Participants were eligible if they had cancer pain (Integrated Palliative care Outcome Scale: IPOS ≥2) and delirium at the time that their Palliative Performance Scale had declined to ≤20 (day 1, immediately before death). Measurements: Pharmacological strategies, pain levels (using the IPOS), and delirium symptoms (using the Memorial Delirium Assessment Scale, item-9). Results: Among a total of 1896 patients, 1396 were assessed for eligibility on day 1, and 137 met the inclusion criteria for analysis. A total of 86 (63%) patients had agitated delirium (hyperactive or mixed) with a median survival time of three days. Regarding pharmacological strategies, 32 (23%) received opioid initiation/dose escalation and 94 (69%) received regular administration of antipsychotics. These figures also included 25 (18%) patients who received both opioid initiation/dose escalation and antipsychotics. Approximately 55% of all patients had persistent cancer pain (IPOS for pain ≥2) on day 2. Among those with agitated delirium, 79% continued to exhibit agitation symptoms on day 2. Conclusion: Despite specialized palliative care, the combined distress of cancer pain and delirium in the last days of life remains complex and refractory.